Skip to main content
. 2021 Feb 25;2021:8819231. doi: 10.1155/2021/8819231

Figure 2.

Figure 2

Treatment with the combination of CLI-095 and resveratrol synergistically inhibits MMP3 and MMP9 expression in ox-LDL- and LPS-activated platelets. Platelets were pretreated with or without CLI-095 (0.1, 0.3, and 1 μM) for 10 min, and then, ox-LDL (0.1 mg/ml) was added for another 10 min. (a) CLI-095 inhibited MMP3 and MMP9 expression that was induced by ox-LDL. (b) CLI-095 inhibited MMP3 and MMP9 expression that was induced by LPS. (c) Resveratrol inhibited MMP3 secretion that was induced by ox-LDL. (d) Resveratrol inhibited MMP9 secretion that was induced by ox-LDL. (e) Resveratrol and CLI-095 synergistically inhibited MMP3 and MMP9 expression that was induced by ox-LDL. (f) Resveratrol and CLI-095 synergistically inhibited MMP3 and MMP9 expression that was induced by LPS. The data represent three independent experiments. #p < 0.05, ##p < 0.01, significant difference between non-ox-LDL-treated platelets and ox-LDL- or LPS-treated platelets; ∗p < 0.05, ∗∗p < 0.01, significant difference between CLI-095-treated platelets and ox-LDL- or LPS-activated platelets.